Despite the use of newer chemotherapeutic agents, survival of patients with advanced/metastatic NSCLC after first- or second-line chemotherapy seems to have reached a plateau ([Carney, 2002](#bib5){ref-type="other"}). Further improvement in treatment is likely to require integration of novel, molecular agents such as EGFR inhibitors. The BR.21 placebo-controlled trial of erlotinib demonstrated that therapy with this EGFR tyrosine kinase inhibitor (TKI) was associated with statistically significant and clinically relevant differences in terms of overall and progression-free survival compared to the placebo ([Shepherd *et al*, 2005](#bib33){ref-type="other"}). Conversely, in a similar study with gefitinib, (ISEL trial), a survival benefit was not demonstrated ([Thatcher *et al*, 2005](#bib39){ref-type="other"}). Several clinical factors have been correlated with response to TKIs, including never-smoking status, female sex, Asian ethnicity and adenocarcinoma histology ([Fukuoka *et al*, 2003](#bib11){ref-type="other"}; [Kris *et al*, 2003](#bib21){ref-type="other"}; [Miller *et al*, 2004](#bib25){ref-type="other"}; [Shepherd *et al*, 2005](#bib33){ref-type="other"}). In addition, several groups have shown that somatic mutations in the tyrosine kinase domain of the EGFR gene, in the exons 18 (G719A/C/S), 19 (DEL19, in-frame deletions which eliminate four to six amino acids just downstream of a critical lysine residue at position 745) and 21 (L858R) (commonly reported as 'classical\' mutations), were significantly correlated with clinical response to gefitinib therapy ([Lynch *et al*, 2004](#bib22){ref-type="other"}; [Paez *et al*, 2004](#bib28){ref-type="other"}; [Eberhard *et al*, 2005](#bib10){ref-type="other"}; [Tsao *et al*, 2005](#bib41){ref-type="other"}). Patients with 'classical\' EGFR mutations exhibit objective responses ranging from 75 to 95% ([Huang *et al*, 2004](#bib15){ref-type="other"}; [Han *et al*, 2005](#bib12){ref-type="other"}; [Mitsudomi *et al*, 2005](#bib26){ref-type="other"}; [Taron *et al*, 2005](#bib38){ref-type="other"}; [Tokumo *et al*, 2005](#bib40){ref-type="other"}; [Inoue *et al*, 2006](#bib16){ref-type="other"}; [Yoshida *et al*, 2007](#bib43){ref-type="other"}). Furthermore, recently it was reported that polysomy or amplification of the EGFR gene but not EGFR mutational status was associated with clinical outcome of patients treated with erlotinib ([Hirsch *et al*, 2005](#bib13){ref-type="other"}; [Tsao *et al*, 2005](#bib41){ref-type="other"}; [Dziadziuszko *et al*, 2006](#bib9){ref-type="other"}).

Although classical EGFR mutations are present in most cases of NSCLC responding to TKIs therapy, approximately 10--20% of patients who do show a clinical response to gefitinib do not have these EGFR mutations, indicating that other, than these classical mutations, may confer sensitivity to TKIs, or that EGFR mutations are not the sole determinants of TKI response ([Sharma *et al*, 2007](#bib32){ref-type="other"}). Since the original reports by [Paez *et al* (2004)](#bib28){ref-type="other"} and [Lynch *et al* (2004)](#bib22){ref-type="other"} several 'other\' mutations of EGFR gene have been reported ([Riely *et al*, 2006b](#bib31){ref-type="other"}). During sequence analysis performed by our group, several mutations of EGFR\'s exons 18, 19 and 21, other than the classical ones, which will be collectively reported in the text as 'other\', have been identified; however, their biological as well as their clinical relevance is still unclear ([Marchetti *et al*, 2005](#bib23){ref-type="other"}). The aim of the present study was to determine whether the presence of these 'other\' variants is correlated with the clinical outcome of patients treated with gefitinib.

In the present study, the clinical outcome of NSCLC patients treated with gefitinib in the context of an expanded access program (EAP) was analysed according to the presence of classical or 'other\' variants of EGFR mutations.

PATIENTS AND METHODS
====================

Patient selection
-----------------

Patients with histologically documented NSCLCs were included in this retrospective analysis. Additional inclusion criteria were as follows: a gefitinib treatment of at least 4 weeks (to evaluate efficacy after adequate exposure to the drug); complete information regarding tumour size, tumour location, extent of disease and prior treatments for NSCLC; bi-dimensionally measurable disease with imaging assessment performed at least 3 weeks before starting gefitinib therapy and at least one subsequent imaging assessment; tumour tissue was required for the assessment of EGFR mutations.

Expanded access program
-----------------------

Gefitinib EAP, was a non-randomised, open-label compassionate use program, which enrolled patients with advanced/metastatic NSCLC. The EAP protocol and informed consent forms were approved by the Scientific and Ethics Committees of the participating Institutions. Patient enrollment began on July 2001 and was closed on April 2006. Eligible patients with NSCLCs (aged⩾18 years) were those who either (i) had disease progression with standard systemic chemotherapy or radiation therapy, or (ii) were ineligible for chemotherapy or radiation therapy, finally.

Treatment
---------

Gefitinib was administered orally, as a once daily dose of 250 mg. Treatment was continued until disease progression, the appearance of unacceptable toxicity or patient\'s withdrawal of consent. Objective tumour responses were evaluated according to WHO response criteria ([Miller *et al*, 1981](#bib24){ref-type="other"}).

Immunohistochemistry
--------------------

Representative, tumour sections from formalin-fixed paraffin-embedded (FFPE) tumour samples were stained immunohistochemically, as described previously ([Koutsopoulos *et al*, 2007](#bib19){ref-type="other"}), using the mouse monoclonal anti-EGFR antibody (clone H11, code M3563, DakoCytomation, Glostrup, Denmark), in dilution 1/50 and incubation time 1 h at room temperature. For the detection of antigen--antibody reaction the Ultra-Vision detection system AP Polymer kit (catalogue no. TL-125-AL, Lab Vision, Cheshire, UK), was used according to the manufacturer\'s instructions. Immunoreaction was considered as weakly positive (2+) when more than 10% of the tumour cells showed weak to moderate complete membrane staining or as strongly positive (3+) when a strong complete membrane staining was observed in more than 10% of the tumour cells. All other staining patterns were interpreted as negative (0 or 1+) ([Koutsopoulos *et al*, 2007](#bib19){ref-type="other"}).

DNA extraction and mutation analysis
------------------------------------

All tumour samples were FFPE tissues. Representative sections from tissue used for DNA extraction were stained with H&E and subjected to histopathologic examination. Subsequently, tissue samples were macrodissected or microdissected (piezo power Eppendorf Microdissector, Germany) to ensure that specimens contained at least 80% tumour cells. Approximately 5--10 *μ*m sections or 30--100 000 cells were collected from normal (when available) and tumour samples and placed in 2% SDS/proteinase K (10 mg ml^−1^) at 56°C overnight. DNA was extracted from the FFPE tissue using the MasterPure Complete DNA/RNA Purification kit (EPICENTRE; Biotechnologies, Madison, USA) according to the manufacturer\'s instructions. Exons 18, 19 and 21 were amplified and subjected to direct sequencing. The PCR primers were as follows:

155273L23(18ex) 5′-TCCCAAACACTCAGTGAAACAAA-3′, 155348L22(18ex) 5′-TGGTCTCACAGGACCACTGATT-3′, 154838U22(18) 5′-TCAGAGCCTGTGTTTCTACCAA-3′, 154899U20(18) 5′-TCCAAATGAGCTGGCAAGTG-3′, 55634U24(19ex) 5′-AAATAATCAGTGTGATTCGTGGAG-3′, 156027L20(19) 5′-TGTGGAGATGAGCAGGGTCT-3′, 156107L22(19ex) 5′-GAGGCCAGTGCTGTCTCTAAGG-3′, 155750U20(19) 5′-GTGCATCGCTGGTAACATCC-3′, 173160L22(21Ex) 5′-CAGCTCTGGCTCACACTACCAG-3′, 173076L19(21) 5′-CATCCTCCCCTGCATGTGT-3′, 172656U22(21Ex) 5′-GCAGCGGGTTACATCTTCTTTC-3′, 172747U19(21) 5′-GCTCAGAGCCTGGCATGAA-3′. The first PCR was carried out in total volume of 10 *μ*l containing 1/10 of the extracted genomic DNA using 1 U of Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad, CA, USA). The initial denaturing step was 94°C for 15 min, followed by 35 cycles of denaturing step at 94°C for 20 s, annealing step at 60°C for 30 s and extension step at 72°C for 1 min, ending with a final extension step at 72°C for 7 min. Nested PCR was carried in a total volume of 20 *μ*l and the conditions were identical to the first PCR. Cycle sequencing reactions were performed using the nested PCR primers and the ABI BigDye Terminator kit (v3.1, Applied Biosystems, Foster City, CA, USA) and electrophoresed on an ABI3100 genetic analyzer (Applied Biosystems). Sequence variants were determined using the Seqscape software (Applied Biosystems) and confirmed by an independent PCR amplification and sequencing in both directions.

Statistical analysis
--------------------

Descriptive statistics for the patient group are reported as median and range. Statistical comparisons between group rates (proportions) were assessed by Pearson\'s *χ*^2^-test or Fisher\'s test where appropriate ([Altman, 1991](#bib1){ref-type="other"}). As this was a compassionate use program, the primary outcome variables were safety, survival and assessment of response. Overall survival (OS) was measured from entry into the study until death; 1-year survival was estimated using the Kaplan--Meier method ([Collet, 1994](#bib7){ref-type="other"}).

RESULTS
=======

Patients\' demographics
-----------------------

Eighty-six patients with a median age of 61 years (range=35--82) were enrolled in the present analysis. Most of the patients (75%) were male, 53 (61.6%) had an adenocarcinoma histology and 61 (79%) had stage IV disease. A total of 28 (33%) patients were never-smokers. All patients had received a platinum-based chemotherapy, except two patients with severe heart failure, which precluded cisplatin administration. A total of 66 patients had gefitinib as third-line treatment; 14 patients (21%) received taxane-based second-line therapy, 21 (32%) a platinum-based therapy while the remaining 31 (47%) received a gemcitabine or irinotecan-based regimen as second-line treatment. Patients\' characteristics are presented in [Table 1](#tbl1){ref-type="table"}. EGFR membrane expression was assessed by immunohistochemistry in all tumour specimens; A total of 42 (49%) of these specimens were considered as positive (2+ or 3+) for EGFR expression.

Mutational analysis
-------------------

EGFR mutation detection was performed by sequencing exons 18, 19 and 21 in tumours of all patients (*n*=86) and matched-normal tissue (*n*=22) or blood (*n*=3) of patients carrying EGFR mutations.

According to the mutational status, three groups of patients were identified as follows: (i) the 'wild-type\' group (*n*=61 patients; 71%) with no detectable mutations; (ii) 'classical\' mutations group (*n*=11 patients, 13%; 6 of these patients harboured the classical exon 19 deletion, one the G719D, one the E746V and three the exon 21 L858R point mutation) and (iii) the 'other\' mutations group (*n*=14 patients, 16%). EGFR mutational status is presented in [Table 2](#tbl2){ref-type="table"}. None of the reported EGFR mutations was found in matched-normal tissues suggesting their somatic origin and eliminating the possibility to be single-nucleotide polymorphisms. A total of 8 (57%) cases had 'other\' mutations that have been previously reported and 6 cases had novel EGFR mutations.

A total of 1 (1.1%) patient (no. 13) had two 'other\' mutations, while 3 (3.4%) patients (nos. 9, 11 and 18), who were included in the 'classical mutations\' group, had both the exon 21 L858R mutation and an 'other\' mutation ([Table 3](#tbl3){ref-type="table"}). The incidence of 'classical\' mutations was gender -- (9.4% for males *vs* 22.7% for females; *P*=0.139) and histology -- (11.8% in adenocarcinomas *vs* 14.3% in non-adenocarcinomas; *P*=0.752) independent, while it was significantly higher in 'never-smoker\' patients compared to 'smokers\' (32 *vs* 2.1%, respectively; *P*=0.001). Similarly, regarding the 'other\' variants, there was no difference in their incidence according to sex (male *vs* female: 18.8 *vs* 13.6%, *P*=0.750), histology (adenocarcinoma *vs* other: 15.7 *vs* 20.0%, *P*=0.773) and smoking habits (smoker *vs* never-smoker: 20.8 *vs* 8.0%, *P*=0.200). Finally, no correlation was observed between EGFR expression as assessed by IHC and presence of 'classical\' mutations (*P*=0.732); conversely, the detection of 'other\' variants was more frequent in patients with tumours, which did not express EGFR by IHC (28.9 *vs* 8.3%, *P*=0.036).

Treatment
---------

The median duration of gefitinib administration was 17 weeks (range=4--140). The reason for treatment discontinuation was disease progression in all but six (6.9%) patients (drug-related toxicity (*n*=3 patients) and personal reasons non-related to treatment or the disease (*n*=3 patients)). There was no clear association between treatment duration and any of the following: PS (*P*=0.262), histology (*P*=0.751), disease stage (*P*=0.103), smoking status (*P*=0.950), sex (*P*=0.663) and skin rash (*P*=0.357) and EGFR expression by IHC (*P*=0.254). However, patients belonging to the group with 'classical\' mutations had significantly longer treatment duration when compared with patients of the 'wild-type\' group (67 weeks *vs* 17 weeks, respectively; *P*=0.018), while there was a trend towards longer treatment duration when compared with patients belonging to group of 'other\' mutations (67 *vs* 21 weeks, respectively; *P*=0.069). On the contrary, there was no significantly different treatment duration between patients belonging to the 'other\' mutations and those of the 'wild-type\' group (21 and 17 weeks, respectively; *P*=0.141).

Response to treatment
---------------------

No patient achieved a complete response, while six (7.0%) experienced a partial response (PR) (overall response rate=7.0%; 95% CI=1.59--12.36) and 40 (46.5%) stable disease (SD); the disease control rate (DCR; PR+SD) was 53.5% (95% CI=42.95--64.03%). Additionally, progressive disease (PD) was observed in 40 (46.5%) patients. Disease control rate was significantly higher for the following: (i) patients with PS 0--1 as compared with those with PS⩾2 (67 and 22%, respectively; *P*\<0.001); (ii) women as compared to men (77.3 and 42.9%, respectively; *P*=0.007); (iii) never-smokers *vs* smokers (84 and 34%, respectively; *P*\<0.001) and (iv) patients who developed skin rash as compared with those who did not (85.2 and 35.7%, respectively; *P*=0.003). In addition, there was a trend towards a higher DCR in patients with adenocarcinoma compared with those bearing other histologic types (54.9 and 47.1%, respectively; *P*=0.057). Regarding patients achieving SD, significant association was observed for those with a PS of 0--1 (*P*=0.003), never-smoker status (*P*=0.001) and development of skin rash (*P*=0.003); conversely, there was no association between DCR and sex (*P*=0.053) or histology (*P*=0.355) ([Table 4](#tbl4){ref-type="table"}).

The DCR was significantly higher in patients of the 'classical\' mutations than in patients of the 'wild-type\' (90.9 and 43.3%, respectively; *P*=0.006) group; conversely, there was no significant difference between the DCR observed in patients of the 'classical\' mutations group and that of patients of the 'other mutations\' group (90.9 and 57.1%, respectively; *P*=0.090) or of patients of the 'other mutations\' group and those of the 'wild-type\' group (57.1 and 43.3%, respectively; *P*=0.386). All patients (six out of six) with exon 19 deletion achieved disease control (two patients achieved PR and four SD); in addition, two out of three patients with exon 21 L858R mutation experienced disease control (one patient with PR and one with SD) while both patients with the G719D and E746V point mutations achieved SD. In the multivariate analysis, the presence of mutations (either 'classical\', or 'other\', as well as all patients with mutations) did not emerge as a significant factor associated with DCR or SD.

Time to tumour progression
--------------------------

The median follow-up period was 109 weeks and the median time to tumour progression (TTP) 20 weeks (range=4--140). A total of 23 (36%) patients had a TTP\>24 weeks and 7 (10.9%) \>52 weeks ([Table 5](#tbl5){ref-type="table"}). There was no difference in TTP according to sex (*P*=0.468), histology (*P*=0.676), EGFR positivity (by IHC) (*P*=0.267) and PS (*P*=0.437); conversely, patients who had never-smoked and patients who developed skin rash had significantly higher TTP (*P*=0.003 and *P*=0.006, respectively). Time to tumour progression in the 'classical\' mutations group was significantly longer than in the 'wild-type\' group (64 *vs* 16 weeks; *P*=0.002, [Figure 1](#fig1){ref-type="fig"}). On the contrary, there was no difference in TTP between 'other\' mutations group and 'wild-type\' group (21 *vs* 16 weeks; *P*=0.363) while there was a trend towards a significant difference in TTP between 'other\' mutation group and 'classical\' mutations group (21 *vs* 64 weeks; *P*=0.069). Although patients with DEL19 mutation had numerically higher TTP, when compared with L858R mutation patients, this difference failed to reach statistical significance (80 *vs* 64 weeks, *P*=0.786).

Survival
--------

Median OS was 48 weeks (range=4--140). None of the following factors had a significant impact on OS: PS (*P*=0.403), histology (*P*=0.198), smoking (*P*=0.242), sex (*P*=0.475), skin rash (*P*=0.182) and EFGR IHC expression (*P*=0.637). Median OS was significantly longer in patients with the DEL19 mutation (not reached) compared to 'wild-type\' patients (36 weeks; *P*=0.043, [Figure 2](#fig2){ref-type="fig"}); however, when all patients with 'classical\' mutations were included in the analysis, this difference was lost (78 *vs* 36 weeks; *P*=0.052, [Figure 3](#fig3){ref-type="fig"}); there was no statistically significant difference regarding OS between patients with DEL19 and L858R mutation (not reached *vs* 78 weeks, *P*=0.896). Similarly, patients of the 'other\' mutation group had a median survival of 67 weeks, which was not different when compared with 'wild-type\' group (*P*=0.094) or 'classical\' mutations group (*P*=0.491). Efficacy results according to mutational status are presented in [Table 6](#tbl6){ref-type="table"}.

DISCUSSION
==========

The incidence of the classical somatic mutations has been reported to range between 3 and 13% in Caucasian populations and between 30 and 40% in populations of Asian descent ([Shigematsu *et al*, 2005](#bib34){ref-type="other"}; [Calvo and Baselga, 2006](#bib4){ref-type="other"}). In a Greek study ([Murray *et al*, 2006](#bib27){ref-type="other"}), somatic mutations of EGFR were reported in 15% of a group of 60 patients with NSCLC, while [Dova *et al* (2007)](#bib8){ref-type="other"} reported two mutations in 50 Greek patients with cancer of unknown primary. In our series, mutational analysis revealed the presence of 'classical\' mutations in 11 (13%) patients which is in agreement with other reports ([Murray *et al*, 2006](#bib27){ref-type="other"}; [Dova *et al*, 2007](#bib8){ref-type="other"}), while 14 (16%) patients had 'other\' mutations. A similar high incidence of 'other\' EGFR mutations has been reported by [Tsao *et al* (2005)](#bib41){ref-type="other"} who have also used microdissected FFPE tumour samples. Microdissection of tumour samples with a low percentage and/or uneven distribution of cancer cells allows the detection of mutations with higher sensitivity; this could be the reason for the high incidence of 'other\' mutations observed in our study. On the other hand, the low-DNA template input in PCR could generate false mutations. However, in our case the latter is unlikely, given that the sequence analysis of FFPE normal tissue specimens of 22 patients with EGFR mutations revealed no mutations (data not shown).

The presence of 'other\' mutations in our study was not correlated with sensitivity to gefitinib. Indeed, patients whose tumours harbour 'other\' variants of EGFR mutations had a higher, but not statistically significant, DCR when compared with patients bearing wild-type EGFR. However, this observation should be considered with caution given the small number of patients analysed. On the other hand, tumour growth control was significantly higher (*P*=0.013) in patients who presented the classical EGFR mutations compared to that of patients with wild-type EGFR, as already has been reported ([Argiris *et al*, 2003](#bib2){ref-type="other"}; [Miller *et al*, 2004](#bib25){ref-type="other"}; [Han *et al*, 2005](#bib12){ref-type="other"}; [Kim *et al*, 2005](#bib18){ref-type="other"}; [Thatcher *et al*, 2005](#bib39){ref-type="other"}; [Tsao *et al*, 2005](#bib41){ref-type="other"}). Similarly, although patients with 'other\' EGFR mutations had a numerically longer survival as compared with patients of the 'wild-type\' group, this difference failed to reach statistical significance. This observation may suggest that, collectively, 'other\' EGFR mutation variants *per se* could not be considered as predictors of clinical outcome.

Furthermore, there was a trend towards higher survival for patients with classical mutations, when compared with 'wild-type\' patients, but this difference failed to reach statistical significance. A possible reason for this observation is the small number of patients studied. This observation is similar with that reported in the BR.21 study ([Tsao *et al*, 2005](#bib41){ref-type="other"}) but it is in conflict with that reported by other studies ([Hirsch *et al*, 2005](#bib13){ref-type="other"}; [Takano *et al*, 2005](#bib37){ref-type="other"}). However, patients with exon 19 deletions had significantly longer survival than patients of the 'wild-type\' group; it should be interesting to mention that patients with EGFR exon 19 deletions are reported to have a longer survival than patients with EGFR L858R point mutations when treated with TKIs ([Mitsudomi *et al*, 2005](#bib26){ref-type="other"}; [Jackman *et al*, 2006](#bib17){ref-type="other"}; [Riely *et al*, 2006a](#bib30){ref-type="other"}).

In the original reports by [Lynch *et al* (2004)](#bib22){ref-type="other"} and [Paez *et al* (2004)](#bib28){ref-type="other"}, only one mutation per tumour was detected. However, subsequent studies demonstrated the presence of more than one mutation per tumour sample ([Huang *et al*, 2004](#bib15){ref-type="other"}; [Pao *et al*, 2004](#bib29){ref-type="other"}; [Taron *et al*, 2005](#bib38){ref-type="other"}; [Murray *et al*, 2006](#bib27){ref-type="other"}). In the present study, four patients had both a 'classical\' and 'other\' mutation variants; three of them achieved SD ([Table 3](#tbl3){ref-type="table"}). However, definitive conclusions cannot be drawn, given the small number of patients and the little amount of data presented in the literature.

In summary, our findings demonstrate that classical but not 'other\' mutation variants of EGFR gene are associated with a higher DCR and better TTP; however, EGFR mutational status should not be considered as the only predictor of response to TKIs since disease control with gefitinib has also been observed in patients without EGFR mutations. Patients harbouring 'other\' EGFR mutation variants have a clinical comportment comparable with that of patients with wild-type EGFR; although this observation strongly suggests that these mutations *per se* could not confer sensitivity to TKTs, we cannot exclude that some of these mutations could be of clinical relevance. Therefore, it should be of importance to establish a large international database of 'other\' EGFR mutation variants, to better understand and evaluate their clinical relevance.
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![Kaplan--Meier survival curve of patients with the 'classical\' DEL19 mutation and wild-type EGFR.](6604068f3){#fig3}

###### 

Patients\' characteristics

                              ***n***      **%**
  -------------------------- ---------- -----------
  *Age*                                 
   Median                        61     
   (minimum--maximum)          35--82   
                                              
  *Sex*                                 
   Male                          64         75
   Female                        22         26
                                              
  *Histology*                           
   Adenocarcinoma             47 (53)    55 (61.6)
   Squamous cell carcinoma    27 (29)    31 (33.7)
   Large cell carcinoma          1        1 (1.1)
   Bronchoalveolar               4        5 (4.7)
   Other                         7        8 (9.3)
                                              
  *PS (WHO)*                            
   0--1                          53         62
   ⩾2                            33         38
                                              
  *Stage*                               
   IIIB                          25         21
   IV                            61         79
                                              
  *EGFR expression (IHC)*               
   0--1+                         44         51
   2--3+                         42         49
                                              
  *Line of therapy*                     
   2nd                           20         24
   ⩾3rd                          66         76
                                              
  *Smoking status*                      
   Smoker                        39         45
   Ex-smoker                     19         22
   Never-smoker                  28         33
                                              
  *No. of organs involved*              
   1                             19         22
   2                             48         56
   ⩾3                            19         22
   Median (range)             2 (1--4)        

###### 

Results of EGFR mutational analysis

  **Patients no.**   **'Classical mutations\' group**   **'Other mutations\' group**   **Histology**      **Gender**   **Smoking status**   **Response**    
  ------------------ ---------------------------------- ------------------------------ ------------------ ------------ -------------------- -------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  1                  DEL 19                                                            Squamous           Male         Never-smoker         SD              
  2                                                     Y727H                          Squamous           Male         Smoker               SD             Y727C (273T cell line) reported ([Stabile *et al*, 2005](#bib35){ref-type="other"})
  3                  DEL 19                                                            Adenocarcinoma     Male         Never-smoker         SD              
  4                                                     V843I                          Squamous           Male         Ex-smoker            SD             V843I reported ([Koyama *et al*, 2006](#bib20){ref-type="other"})
  5                                                     L747S                          Adenocarcinoma     Female       Never-smoker         SD             L747P reported ([Sunaga *et al*, 2007](#bib36){ref-type="other"})
  6                  G719D                                                             Adenocarcinoma     Male         Never-smoker         SD              
  7                  DEL 19                                                            Adenocarcinoma     Female       Never-smoker         PR              
  8                                                     P691S                          Adenocarcinoma     Male         Ex-smoker            SD             Novel
  9                  L858R, L861P                                                      Undifferentiated   Male         Smoker               PD              
  10                                                    K860E                          Squamous           Male         Smoker               PD             Novel
  11                 L858R, V843I                                                      Adenocarcinoma     Female       Never-smoker         SD              
  12                                                    G863S                          Adenocarcinoma     Female       Never-smoker         SD             G863D reported ([Bell *et al*, 2005](#bib3){ref-type="other"}; [Chou *et al*, 2005](#bib6){ref-type="other"}; [Riely *et al*, 2006b](#bib31){ref-type="other"})
  13                                                    T847A, G863S                   Adenocarcinoma     Male         Smoker               PD             T847I reported ([Tsao *et al*, 2005](#bib41){ref-type="other"})
  14                                                    L692P                          Squamous           Male         Smoker               PD             Possible non-somatic
  15                                                    L703F                          Adenocarcinoma     Female       Smoker               PD             L703V reported ([Takano *et al*, 2005](#bib37){ref-type="other"}; [Riely *et al*, 2006b](#bib31){ref-type="other"})
  16                 E746V                                                             Adenocarcinoma     Female       Never-smoker         SD              
  17                                                    G729R                          Undifferentiated   Male         Smoker               PD             G729E reported ([Willmore-Payne *et al*, 2006](#bib42){ref-type="other"})
  18                 L858R, E709K                                                      Squamous           Female       Never-smoker         PR              
  19                                                    V726M                          Adenocarcinoma     Male         Smoker               SD             Novel
  20                 DEL19                                                             Adenocarcinoma     Male         Never-smoker         PR              
  21                 DEL19                                                             Squamous           Male         Never-smoker         SD              
  22                                                    G857E                          Adenocarcinoma     Male         Smoker               SD             Reported ([Hsieh *et al*, 2006](#bib14){ref-type="other"})
  23                                                    E711K                          Squamous           Male         Smoker               PD             Novel
  24                 DEL19                                                             BAC                Female       Never-smoker         SD              
  25                                                    G874S                          Adenocarcinoma     Female       Smoker               SD              
  Total              11                                 14                                                                                                  

###### 

Clinical characteristics of patients bearing both a classical and an 'other\' mutation

  **Patients no.**   **Sex**   **Histology**      **Smoking status**   **Response to gefitinib**   **Duration**    
  ------------------ --------- ------------------ -------------------- --------------------------- -------------- -------------
  9                  Male      Undifferentiated   Smoker               PD                          ---            L858R-L861P
  11                 Female    Adenocarcinoma     Never-smoker         SD                          64 weeks       L858R-V843I
  18                 Female    Squamous           Never-smoker         PR                          12 weeks       L858R-E709K

###### 

Clinical and molecular characteristics of patients achieving disease control

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       ***n***    **Female sex *n* (%)**   **Adenocarcinoma histology^a^ *n* (%)**   **Never smoker *n* (%)**   **Skin rash development *n* (%)**  **EGFR mutations**
  ---- --------- ------------------------ ----------------------------------------- -------------------------- ----------------------------------- ------------------------------
  PR   6                 4 (67%)                           2 (33%)                            5 (83)                         4 (67%)               *DEL 19: n*=2 (33%)\
                                                                                                                                                   *L858R: n*=1 (17%)\
                                                                                                                                                   *Wild type: n*=3 (50%)

  SD   40                14 (35%)                         28 (70%)                           18 (45%)                      19 (47.5%)              *DEL 19: n*=4 (10%)\
                                                                                                                                                   *L858R: n*=1 (2.5%)\
                                                                                                                                                   *Other variant: n*=10 (25%)\
                                                                                                                                                   *Wild type: n*=25 (62.5%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PR=partial response, SD=stable disease.

Bronchoalveolar included.

###### 

EGFR mutation status for patients with ⩾24 and ⩾52 weeks TTP

  **TTP**     ***n***    **Wild type**   **Exon 19 deletion**   **L858R**   **Other variant**
  ----------- --------- --------------- ---------------------- ----------- -------------------
  ⩾24 weeks   23           11 (48%)            5 (22%)           1 (4%)          6 (26%)
  ⩾52 weeks   7             1 (14%)            2 (29%)           1 (14%)         3 (43%)

###### 

Efficacy results according to mutational status

         **'Classical\' mutations**   **'Other\' mutations**   **Wild type**
  ----- ---------------------------- ------------------------ ---------------
  DCR            90.9%^\*^                    57.1%                43.3
  TTP           64 weeks^\*^                 21 weeks            16 weeks
  OS           78 weeks^\*\*^                67 weeks            36 weeks

DCR=disease control rate, OS=overall survival; TTP=time to tumour progression.

*P*\<0.05 (*vs* wild type).

*P*=0.052 (*vs* wild type).

[^1]: Drs AG Pallis and A Voutsina have contributed equally to this work.
